Edesa Biotech (EDSA) Net Cash Flow (2013 - 2025)
Edesa Biotech (EDSA) posted Net Cash Flow of $1.3 million for Q4 2025, up 183.02% sequentially from -$1.5 million in Q3 2025, and up 126.47% YoY from $554342.0 in Q4 2024.
Edesa Biotech (EDSA) Net Cash Flow (2013 - 2025) Analysis & Trends
Edesa Biotech has reported Net Cash Flow for 13 years, with the latest figure at $1.3 million in Q4 2025.
- Quarterly Net Cash Flow rose 126.47% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.4 million (up 493.24% YoY) and the FY2025 annual result came in at $9.7 million, up 325.88% from the prior year.
- Net Cash Flow advanced to $1.3 million in Q4 2025 per EDSA's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $12.4 million in Q1 2025 and troughed at -$5.6 million in Q3 2022.
- A 5-year average of $288674.2 and a median of -$1.0 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2021 and 2025: Net Cash Flow slumped 11201.23% in 2021, then soared 955.36% in 2025.
- Over 5 years, Net Cash Flow stood at -$2.0 million in 2021, then surged by 156.54% to $1.1 million in 2022, then sank by 198.22% to -$1.1 million in 2023, then jumped by 150.36% to $554342.0 in 2024, then soared by 126.47% to $1.3 million in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $1.3 million, -$1.5 million, and -$1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.26 Mn |
| Dec 31, 2025 | 1.26 Mn |
| Sep 30, 2025 | -1.51 Mn |
| Sep 30, 2025 | -1.51 Mn |
| Jun 30, 2025 | -1.70 Mn |
| Jun 30, 2025 | -1.70 Mn |
| Mar 31, 2025 | 12.39 Mn |
| Mar 31, 2025 | 12.39 Mn |
| Dec 31, 2024 | 554,342.00 |
| Dec 31, 2024 | 554,342.00 |
| Sep 30, 2024 | -1.01 Mn |
| Sep 30, 2024 | -1.01 Mn |
| Jun 30, 2024 | -750,454.00 |
| Jun 30, 2024 | -750,454.00 |
| Mar 31, 2024 | -1.45 Mn |
| Mar 31, 2024 | -1.45 Mn |
| Dec 31, 2023 | -1.10 Mn |
| Dec 31, 2023 | -1.10 Mn |
| Sep 30, 2023 | -1.02 Mn |
| Sep 30, 2023 | -1.02 Mn |